Thursday, 13. October 2016
IDT Biologika to highlight its role as a reliable partner for extraordinary vaccine and parenteral biologics solutions
IDT Biologika (Booth 3R20), a global, fully integrated state-of-the-art contract development and manufacturing organization (CDMO) that develops industrial processes and makes breakthrough biologics to benefit human and animal health, announced today its participation at the CPhI Worldwide Conference and Exhibition, currently taking place at the Fira de Barcelona, Gran Via, Barcelona, Spain, through October 6, 2016.
“Our core competencies in viral and microbial vaccines and in gene and cancer therapeutic products are underscored by our commitment to outstanding quality and operational excellence. We are receiving increased global recognition for our best-in-class process development and cGMP manufacturing capabilities,” says Dr. Ralf Pfirmann, Chief Executive Officer of IDT Biologika. “With unique technologies and technical acumen that drive our aseptic processing, with a live virus and cytotoxic expertise unrivaled in the industry, we provide innovative and sustainable technologies to support our clients’ manufacturing goals.”
IDT Biologika, who has representatives available at Hall 3, Booth 3R20 at the CPhI conference, offers global expertise from a century of experience in the life sciences industry, and provides seamless end-to-end solutions for client CDMO needs. The company has enhanced its offered range of CDMO services by a production upgrade at its site in Rockville, Maryland. “While the scale of our nimble technologies in Rockville allows us to specialize in the complex and varied processes inherent in preclinical through phase II projects, we harmonize with IDT´s headquarters in Germany to produce later clinical-stage and commercial-stage products for our clients,” says Dr. Pfirmann.
“Multinational pharmaceutical companies, biotechs and vaccine developers need industrial development and manufacturing partners that can navigate nimbly along the breadth and depth of the manufacturing needs at different stages of the development chain,” highlights Dr. Andreas Neubert, Chief Science Officer at IDT Biologika. “The earlier phases, in particular, often require multiple approaches and platforms, newly developed processes, and complex integrated assays that play a significant part of developing the optimal solution for manufacturing projects. We are capable of meeting all of these needs.”
Dr. Pfirmann adds: ”We as IDT Biologika work seamlessly from preclinical through development and commercialization. We are the ideal and experienced partner for prophylactic and therapeutic vaccines and gene and cancer therapy products. We have the right assays to deal with difficult and complex subject matter, and see our clients’ projects through to the end.”
At its site in Dessau, Germany, IDT continuously expands its production capabilities offering leading state-of-the-art manufacturing technology from bulk drug substance to sterile filling through efficient packaging and cold chain. Services range from pharmaceutical development through distribution-ready packaging of final drug products, with flexible capacities from clinical test samples to commercial production.